
Pathology Bites: Agilent’s Acquisition of Proscia: What Comes Next? With CEO David West
What does Agilent’s planned acquisition of Proscia mean for the laboratories, pathologists and technology partners using its software and for the future of digital pathology? After the acquisition was announced the Pathology News team took the opportunity to get into detail with David West, CEO of Proscia. Proscia co-founder and CEO David West joins Sidney Ocanagil-Tunstall to discuss the thinking behind the deal, why Agilent felt like the right partner, and what joining forces could make possible. From Proscia’s early beginnings to its role in diagnostic laboratories and pharmaceutical research, David reflects on the company’s growth and the ambitions driving its next chapter. The conversation tackles the questions that matter to customers: will Proscia retain its commitment to interoperability and vendor choice? What happens to its leadership and brand? And how could combining digital pathology, AI and Agilent’s companion diagnostics capabilities create new opportunities? Watch the full conversation for David’s perspective on the deal, the commitments behind it and what lies ahead.


















